Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.73 |
| ▸ | JAK3 | P52333 | 1/20 | 0.68 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1190971 | 1.00 | EGFR (0.74) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL1190009 | 0.97 | EGFR (0.72) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL1190010 | 0.97 | EGFR (0.72) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL1192069 | 0.95 | EGFR (0.70) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL29623422 | 0.94 | EGFR (0.75) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL208102 | 0.94 | EGFR (0.75) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL185179 | 0.94 | EGFR (0.75) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL3578016 | 0.93 | EGFR (0.72) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL3578019 | 0.93 | EGFR (0.72) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL185032 | 0.92 | EGFR (0.78) | EGFRERBB2JAK3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1731511-B1 | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA (DE) | 2015-08-12 | — | — | EP | claimed |
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG. (DE) | 2010-12-09 | — | — | US | claimed |
| US-20100144639-A1 | USE OF INHIBITORS OF THE EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) / PROSTATIC HYPERTROPHY | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-10 | — | — | US | claimed |
| US-20100010023-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-01-14 | — | — | US | claimed |
| US-20090306072-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | claimed |
| US-20070099918-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-03 | — | — | US | claimed |
| US-20060178364-A1 | Use of EGFR tyrosinkinase inhibitors for treatment of chronic rhinosinusitis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-10 | — | — | US | claimed |
| US-20060100223-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | claimed |
| EP-1521595-B1 | NOVEL DRUG COMPOSITIONS BASED ON NOVEL ANTICHOLINERGICS AND INHIBITORS OF EGFR-KINASE | BOEHRINGER INGELHEIM PHARMA (DE) | 2006-03-15 | — | — | EP | claimed |
| US-20050165013-A1 | Pharmaceutical compositions containing anticholinergics and EGFR kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-28 | — | — | US | claimed |
| US-20050148562-A1 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-07 | — | — | US | claimed |
| US-20040048887-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| US-20030225079-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-04 | — | — | US | claimed |
| US-20030158196-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2003-08-21 | — | — | US | claimed |
| US-20030149062-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-08-07 | — | — | US | claimed |
| US-20020173509-A1 | Quinazoline derivatives and phamaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-21 | — | — | US | claimed |
| US-8722694-B2 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2014-05-13 | — | — | US | disclosed |
| US-8586608-B2 | Quinazoline derivatives and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20030149062-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-08-07 | — | — | US | disclosed |
| US-20020173509-A1 | Quinazoline derivatives and phamaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306072-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885JAK3 54/4885 |
| US-20020173509-A1 | Quinazoline derivatives and phamaceutical compositions containing them | MAP3K1, MAP4K2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 195/4885ERBB2 78/4885JAK3 45/4885 |
| US-20060100223-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | CNKSR1, RET, ABL1 | EGFR 200/4885ERBB2 122/4885JAK3 10/4885 |
| US-20100010023-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CNKSR1, ABL1, TYK2 | EGFR 218/4885ERBB2 109/4885JAK3 9/4885 |
| US-20050165013-A1 | Pharmaceutical compositions containing anticholinergics and EGFR kinase inhibitors | CHRM3, EGFR, CHRM2 | EGFR 2/4885ERBB2 4/4885JAK3 285/4885 |
| US-20070099918-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy | BPHL, EGFR, ERBB3 | EGFR 2/4885ERBB2 4/4885JAK3 654/4885 |
| US-20050148562-A1 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | CHRM3, ADRA2C, PDE3A | EGFR 52/4885ERBB2 96/4885JAK3 124/4885 |
| US-20100144639-A1 | USE OF INHIBITORS OF THE EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) / PROSTATIC HYPERTROPHY | BPHL, EGFR, ERBB3 | EGFR 2/4885ERBB2 4/4885JAK3 654/4885 |
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | PDE4B, CHRM3, ADRA2C | EGFR 43/4885ERBB2 75/4885JAK3 115/4885 |
| US-20030149062-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885JAK3 154/4885 |
| US-20030225079-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | BPHL, EGFR, ERBB3 | EGFR 2/4885ERBB2 4/4885JAK3 654/4885 |
| US-20040048887-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | CHRM3, EGFR, ERBB2 | EGFR 2/4885ERBB2 3/4885JAK3 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.